Immunotherapy最新文献_第2页

Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-14 DOI: 10.1080/1750743X.2025.2479410

Afroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, Dimitrios Schizas, Nikolaos Charalampakis

{"title":"Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review.","authors":"Afroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, Dimitrios Schizas, Nikolaos Charalampakis","doi":"10.1080/1750743X.2025.2479410","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2479410","url":null,"abstract":"Immunotherapy for gastrointestinal cancers has elicited considerable amount of attention as a viable therapeutic option for several cancer types. Gut microbiome as a whole plays a critical role in shaping immune responses and influencing cancer progression. Recent evidence suggests that Helicobacter pylori (H. pylori), may influence immunotherapy efficacy by modulating the tumor microenvironment. Infection with H. pylori is common as it affects approximately 50% of the global population and remains the leading risk factor for gastric cancer. Interestingly, recent clinical and preclinical data has associated H. pylori with colorectal cancer carcinogenesis. Gut microbiome appears to be a modulator of the relationship between the immune system, gastrointestinal cancer development and existing therapies. Infection with H. pylori may affect immunotherapy results in both gastroesophageal and colorectal cancer; favorable results were noticed in H. pylori positive patients with gastric cancer, while in colorectal cancer patients the pathogen seemed to impede immunotherapy's action. This article aims to review current data on the role of H. pylori in triggering gastric inflammation and cancer, as well as its potential involvement in colorectal cancer development. Additionally, it seeks to highlight the impact of H. pylori infection on the response to immunotherapy in gastrointestinal cancers.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy for guiding breast cancer immunotherapy.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-14 DOI: 10.1080/1750743X.2025.2479426

Emanuela Fina, Elsa Vitale, Simona De Summa, Gennaro Gadaleta-Caldarola, Stefania Tommasi, Raffaella Massafra, Oronzo Brunetti, Alessandro Rizzo

引用次数: 0

Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-07 DOI: 10.1080/1750743X.2025.2473305

Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Thomas, Yinghong Wang

引用次数: 0

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-18 DOI: 10.1080/1750743X.2025.2478804

Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková

{"title":"Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.","authors":"Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková","doi":"10.1080/1750743X.2025.2478804","DOIUrl":"10.1080/1750743X.2025.2478804","url":null,"abstract":"Aims: This study aimed to examine changes in the repertoire of functional T-cells specific for six leukemia-associated antigens (LAA), including WT1, PRAME, MUC1, CCNA1, NPM1, and NPM1c, during immune reconstitution following allogeneic transplantation of hematopoietic stem cells (HSCT) in patients with acute myeloid leukemia.Patients & methods: LAA-specific T cell response was measured by ELISPOT- IFNγ and intracellular cytokine staining in 47 patients before starting conditioning therapy (baseline) and 7 months after HSCT.Results: The positive cumulative LAA-specific T cell response before HSCT was associated with a decreased risk of relapse after HSCT. The prevalent genetic aberration - an internal tandem duplication of Fms 3 - related receptor tyrosine kinase, which has been previously implicated in immune escape mechanisms, is presented here for the first time as a factor associated with the absence of an adaptive T cell response against multiple LAAs. T-cell specific responses against wild-type and mutated NPM1 antigens were less frequent in the study cohort and did not correlate with mutations in the NPM1 gene.Conclusions: Our results showed that the T-cell response to LAA can be reconstituted after HSCT. Measurement of functional pre-transplant T-cell responses against multiple LAAs could help to find patients with an increased risk of relapse.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"185-190"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-18 DOI: 10.1080/1750743X.2025.2478814

Fahimeh Ezzatizadeh, Azam Bolhassani, Fattah Sotoodehnejad Nematalahi, Abolfazl Fateh

引用次数: 0

Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-17 DOI: 10.1080/1750743X.2025.2461987

Sophie Carlson, Tasha L Lin, Sarah M Larson

引用次数: 0

Immunotherapy rechallenge after significant toxicity - can it be done successfully?

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-24 DOI: 10.1080/1750743X.2025.2452838

Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay

{"title":"Immunotherapy rechallenge after significant toxicity - can it be done successfully?","authors":"Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay","doi":"10.1080/1750743X.2025.2452838","DOIUrl":"10.1080/1750743X.2025.2452838","url":null,"abstract":"Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility.Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge outcomes.Results: 69 of 307 patients (22%) required 124 hospitalizations for irAEs. 8 required ICU admission (2.6%). 6 (1.9%) died from irAEs. Corticosteroids were used in 96% of admissions. Additional immunosuppression was required in 26 admissions (21%). 47 of 69 patients were rechallenged (68%). The median duration between toxicity and rechallenge was 49 days (range 17-994 days). 19 of 47 rechallenged patients (40%) were admitted for subsequent irAE. 19 patients of the rechallenged group (40%) were alive at last follow-up.Conclusion: Immunotherapy rechallenge following prior irAE hospitalization is feasible but carries significant toxicity risk.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"103-111"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Encouraging co-targeting of immunoregulatory molecules in cancer treatment.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-05 DOI: 10.1080/1750743X.2025.2462520

Takumi Sato, Yu Fujiwara

引用次数: 0

Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.1080/1750743X.2025.2467026

Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa, Sunghyun Kim, Yunju Bae, Suyoung Kim, Jeong Eun Park, Jongho Kim, Sarbjit Saini

{"title":"Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.","authors":"Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa, Sunghyun Kim, Yunju Bae, Suyoung Kim, Jeong Eun Park, Jongho Kim, Sarbjit Saini","doi":"10.1080/1750743X.2025.2467026","DOIUrl":"10.1080/1750743X.2025.2467026","url":null,"abstract":"Aims: To demonstrate pharmacokinetic equivalence of CT‑P39 administered via auto-injector (CT‑P39 AI) and European Union-approved reference omalizumab via pre-filled syringe (EU-OMA PFS) in healthy Japanese adults.Participants & methods: This open-label, Phase 1 study randomized participants (1:1) to a single 150 mg/mL dose of CT‑P39 AI or EU-OMA PFS. The primary endpoint was pharmacokinetic equivalence per area under the concentration-time curve from time zero to infinity (AUC0-inf) and maximum serum concentration (Cmax). Equivalence was concluded if the 90% confidence intervals (CIs) for the ratios of geometric least-squares means (gLSMs) were contained within the predefined 80-125% equivalence margin. Secondary endpoints comprised additional pharmacokinetics, pharmacodynamics, safety, and immunogenicity.Results: Overall, 65 and 64 individuals were randomized to CT‑P39 AI and EU-OMA PFS, respectively. Pharmacokinetic equivalence between CT‑P39 AI and EU-OMA PFS was demonstrated for both AUC0-inf (ratio of gLSMs [90% CI] 101.66 [95.31-108.45]) and Cmax (93.91 [87.20-101.14]). Thirty-nine (60.0%; CT‑P39 AI) and 32 (50.8%; EU-OMA PFS) participants experienced treatment-emergent adverse events (TEAEs) with no serious TEAEs. Secondary endpoints were comparable between groups.Conclusions: CT‑P39 AI was pharmacokinetically equivalent to EU-OMA PFS following a single dose in healthy Japanese individuals; pharmacodynamics, safety, and immunogenicity were comparable.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"113-121"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Light-based technologies in immunotherapy: advances, mechanisms and applications.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-03 DOI: 10.1080/1750743X.2025.2470111

Davide Frumento, Ștefan Ţălu

{"title":"Light-based technologies in immunotherapy: advances, mechanisms and applications.","authors":"Davide Frumento, Ștefan Ţălu","doi":"10.1080/1750743X.2025.2470111","DOIUrl":"10.1080/1750743X.2025.2470111","url":null,"abstract":"Light-based immunotherapy uses specific wavelengths of light to activate or modulate immune responses. It primarily employs two mechanisms: direct activation of immune cells and indirect modulation of the tumor microenvironment (TME). Several light-based technologies are under investigation or clinical use in immunotherapy, including photodynamic immunotherapy (PDIT) and photothermal therapy (PTT). Optogenetic tools have the potential to precisely control T-cell receptor activation, cytokine release, or the activity of other immune effector cells. Light-based technologies present innovative opportunities within the realm of immunotherapy. The ability to precisely regulate immune cell activation via optogenetics, alongside the improved targeting of cancer cells through photoimmunotherapy, signifies a transformative shift in our strategies for immune modulation. Although many of these technologies remain in the experimental stage for various applications, initial findings are encouraging, especially concerning cancer treatment and immune modulation. Continued research and clinical trials are essential to fully harness the capabilities of light technology in the context of immune cell therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"123-131"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0